Estrogen receptor (covalent antagonist)

Class

small molecule selective estrogen receptor covalent antagonist (SERCA); developed by Hengrui Pharmaceuticals. Note: at least one drug-database aggregator (Synapse/PatSnap) labels this compound's target class as a 'Ca2+-ATPase inhibitor' — this appears to be an acronym collision (SERCA is also the standard abbreviation for the unrelated sarco/endoplasmic reticulum Ca2+-ATPase calcium pump). Hengrui's own clinical-trial-approval reporting (via PharmCube/ByDrug) is unambiguous that this is an estrogen-receptor covalent antagonist, not a calcium-pump inhibitor; flagging in case that aggregator mislabel has propagated elsewhere.

Pathway

binds potently and selectively to ER, inhibiting ER activity and downstream signaling to suppress tumor cell proliferation in ER-positive, HER2-negative breast cancer; studied as monotherapy and in combination with the CDK4/6 inhibitor SHR6390 (dalpiciclib)

The estrogen receptor (ER) is a nuclear hormone receptor that, when bound by estrogen, moves into the cell nucleus and switches on genes that drive cell division. In many breast cancers, tumor cells retain this receptor and depend on estrogen signaling to grow, a subtype classified as ER-positive. Blocking ER activity is a long-established strategy for treating these cancers, previously achieved by molecules that either compete with estrogen for the receptor or promote its degradation. This mechanism uses a covalent antagonist, a small molecule designed to form a permanent chemical bond with the receptor rather than binding reversibly. Because the interaction is irreversible, the drug can achieve prolonged suppression of receptor activity even after free drug clears from circulation, potentially overcoming resistance mechanisms that arise when tumors adapt to reversible blockers. This approach is being explored both alone and alongside inhibitors of CDK4/6, enzymes that promote cell-cycle progression downstream of growth signaling; combining ER blockade with cell-cycle inhibition targets tumor proliferation through two complementary routes. The broad relevance of this mechanism lies in ER-positive, HER2-negative breast cancer, one of the most common breast cancer subtypes, where sustained hormonal deprivation of tumor cells remains a central therapeutic goal.